Thromboembolic prophylaxis with enoxaparin in non-surgical cancer patients under systemic antineoplastic therapy

Prospective, randomised, controlled open single-centre trial on thromboembolic prophylaxis with Enoxaparin in non-surgical cancer patients under systemic antineoplastic therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN25616445

Enrollment

160

Registered

2008-04-04

Start date

2007-12-03

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thrombosis and pulmonary embolism in cancer patients Circulatory System Thrombosis and pulmonary embolism in cancer patients

Interventions

Enoxaparin 40 mg subcutaneously daily for 24 weeks versus no therapy (because placebo injections are ethically not justifiable).

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Cancer patients 2. Inpatients 3. Treated with systemic antineoplastic therapy 4. Aged 18 - 85 years, either sex 5. One to three of the following factors given: 5.1. Prior thrombosis in medical history 5.2. Thrombosis in family 5.3. Fever 5.4. Elevated C-reactive protein (CRP) 6. Life expectancy greater than 24 weeks

Exclusion criteria

Exclusion criteria: 1. Pregnancy (positive pregnancy test) or lactating 2. Simultaneous participation in another clinical trial 3. Women of child-bearing age without adequate contraception 4. Known heparin-induced thrombocytopenia (HIT) type II

Design outcomes

Primary

Measure	Time frame
Incidence of thrombosis and/or pulmonary embolism. Duration of follow-up: 24 weeks	—

Secondary

Measure	Time frame
1. Safety 2. Overall mortality Duration of follow-up: 24 weeks	—

Countries

Germany

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026